Literature DB >> 33528655

[Current state of vaccination against SARS-CoV-2].

Christof Iking-Konert1, Christof Specker2, Klaus Krüger3, Hendrik Schulze-Koops4, Peer Aries5.   

Abstract

On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; STIKO recommandation; Vaccination; mRNA vaccination

Mesh:

Substances:

Year:  2021        PMID: 33528655      PMCID: PMC7852047          DOI: 10.1007/s00393-021-00966-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  1 in total

1.  Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.

Authors:  Kerri Hagemann; Kristoffer Riecken; Johannes M Jung; Heike Hildebrandt; Stephan Menzel; Madeleine J Bunders; Boris Fehse; Friedrich Koch-Nolte; Fabian Heinrich; Sven Peine; Julian Schulze Zur Wiesch; Thomas T Brehm; Marylyn M Addo; Marc Lütgehetmann; Marcus Altfeld
Journal:  Eur J Immunol       Date:  2022-04-22       Impact factor: 6.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.